At least two classes of genes have been identified, which are important in the pathogenesis of cancer. The first class was originally discovered by the work on acutely transforming RNA tumor viruses and consists of the oncogenes. Activation of these genes by mutation, chromosome translocation or by other means, provides an essential step in the multistage process of malignant transformation. The second class which includes the socalled anti-oncogenes, has been identified in studies of hereditary cancers, in particular Wilms' tumor and retinoblastoma. Whereas oncogenes behave dominantly (one activated copy is sufficient for producing cancer), the antioncogenes show a recessive mode of cancer initiation both alleles have to be inactivated. An example of the first class is the abelson oncogene (c-abl) which seems to play an essential role in chronic myeloid leukemia (CML). CML is Iharacterized by the presence of the Philadelphia (Ph ) chromosome in thelleukemic cells of 96% of all CML patients. The Ph chromosome (22q-) is the result of a reciprocal translocation between chromosome 22 and The availability of human DNA sequences in recomchromosome 9, t(9q34,22qll). previously we described binants has transformed human genetics. There are the localization of the human c-abl oncogene on now approximately five hundred coding gene sequences, chromo~ome 9 and demonstrated its translocation to and innumerable localised anonymous probes, cloned the Ph chromosome in CML patients (1). The cloning and available pure and in unlimited amount. These and analysis of breakpoint fragments revealed that can be used by clinical molecular pathologists to the breakpoints on chromosome 22 all cluster in a study genes in a person-specific way, since any cloned very limited area, the breakpoint cluster region, gene sequence is unique to the person from whom it is bcr (2). Breakpoints on chromosome 9, however, are isolated. Therefore, all of the heritable parameters scattered over a large area. The detection of a of individuality, whether representing pathological chimeric mRNA (5'bcr and 3'abl sequences) in the or normal variation, can be studied by comparing gene leukemic cells of CML patients (3,4) and the cloning sequences.
of chimeric cDNAs from a CML derived cell line K562 Many of the cloned human coding genes which have (5,6) strongly indicate that bcr and c-abl coding been isolated and characterised to date are also in-sequences are linked by RNA splicing, independent volved in single gene pathology. These include the from the distance between the two genes on the Ph 1 sequences known to be mutated so as to cause known chromosome. These findings suggest an important role and characterised Mendelian disorders, such as thalas· for the altered c-abl product in the generation and/ saemia, PKU or haemophilia. In such cases, the under-or maintenance of CML. lying molecular nature of the defect can be deterStrong evidence for the existence of the second mined, and the probe can be used for population-based class of genes the socalled anti-oncogenes comes carrier testing and for uneqUivocal prenatal diagfrom studies of Wilms' tumor and retinoblastoma. nosis. Other common single gene defects of unknown Both tumors seem to be the result of loss or biochemistry, such as cystic fibrosis and Duchenne inactivation of the two alleles of a wild type gene muscular dystrophy, have been linked either to known located on Ilp13 in the case of Wilms' tumor (7) DNA coding sequences, or to anonymous DNA probes and 13q14 in retinoblastoma (8). In the here1itary which are chromosomally localised. In these cases, form of these tumors the first inactivation event is carrier detection and prenatal (or presymptomatic) present in the germ line as a mutation or chromosome diagnosis is only available to informative families deletion, whereas in the non-hereditary cases with living affected members.
(mostly unilaterally affected) the first inactivation A complete map of the human genome will soon be event occurs in the somatic cell. (11) second event in the somatic cell, homozygosity o~hemizygosity of a~ecessive mutation is obtained, leading to the formation of a tumor. As shown by the group of Cavenee (9,10) and others, besides mutation or chromosome deletion, this second step may also involve abnormal chromosomal segregation events during mitosis. As both Wilm's tumor and retinoblastoma are embryonic tumors it is tempting to speculate that the genes involved play a part in the development of the target tissues during embryogenesis. At least two regulators of the IgE response have been distinguished. One is involved in the production of allergen specific IgE antibodies. This regulator segregates in families in linkage to determinants encoded by the major histocompatibility gene complex (HLA). Thus this regulator has been proposed to be encoded by HLA genes. Moreover increased IgE responses have been found to segregate in families. The patterns of inheritance suggest multifactorial expression in spite of more or less clear autosomal dominant or recessive segregation patterns. The hyper IgE syndrome, an immunodeficiency disease accompanied by recurrent infections of the skin in particular, is not associated with allergy. In this syndrome there is evidence that the defect resides in T lymphocytes, involved in the regulation of the IgE level. We have started investigations on regulatory sequences within the Immunoglobulin heavy chain complex on the long arm of chromosome 14. As a first step we try to characterize the V (= variable) genes involved in the IgE response. For this purpose we have performed experiments to establish human IgE producing B cell lines, the results of which to be discussed.
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IMPROVED TOLERANCE TO INHALANT ALLERGENS DURING AN
INTENSIVE COURSE OF RUSH-IMMUNOTHERAPY K. Ende, R. Urbanek, G. Klein University Children's Hospital, Freiburg, FRG Significant reduction in asthmatic symptoms and use of medication was reached by a short term course of allergen immunotherapy. In vivo and in vitro parameters were investigated for their predictive value. Six patients with allergic asthma, 5 sensitized to housedust mite and one with allergy to grasspollen underwent a rush immunotherapy of 8 to 14 days under clinical observation until a maintenance dose was tolerated. Titrated skin test, conjunctival provocation test (CPT), bronchial provocation test (BPT) and allergenspecific IgE and IgG antibodies were examined before and 8 weeks after the dose build-up period. A significant improvement was demonstrated clinically by a decrease in reported symptoms and use of medication as well as by increasing the threshhold of tolerance 10 to 100 fold in skin test, CPT and BPT. Specific IgG antibodies increased in all patients. An intensive short term course of allergen-immunotherapy was shown to be effective in reducing allergic symptoms in patients sensitized to inhalant allergens already within 2 months. Titrated skintest, BPT and specific IgG levels were of predictive value. Allergy serves a particularly good model for understanding the genetics of human immune response and its relationship to disease, since one can establish a clear~relationship between specific IgE antibody responses and the expression of specific allergies (1). There is evidence for at least two types of genetic control of IgE responses in man, namely, HLA-linked control of specific responses and non-HLA-linked control of the overall production of IgE, where high IgE is inherited as a recessive trait
Genetics in
The primary focus will be on our recent studies of specific IgE and IgG antibody responses to the low mol. wt Ambrosia (ragweed) allergens, Amb V (Ra5; refs. 2-5) and Amb VI (Ra6; ref. 6). Three species of Amb V (mol. wts. 4400-5000 D) have been isolated, Amb a V (from A. artemisiifolia, short ragweed ), Amb tV (fromA.trifida, giant ragweed) andAmb p V (from A. psilostachya, western ragweed), as well as another allergen species, Amb a VI (mol. wt. 11,500 D). Immune responsiveness toward all of the Amb V homologues was found to be significantly associated with the Dw2 subspecificity ofHLA-DR2 (4, 5, 7, 8) , even though these molecules show little, or no, antigenic crossreactivity (6). The association with the Amb t V molecule is less striking than with Amb a V andAmb p V, where 95% or more responder subjects possess DR21Dw2. In the case of Amb a VI, 80% of responders possess HLA-DR5 (9).
We have used a refmed version of conventional allergen immunotherapy in a prospective genetic study of immune response to ragweed pollen allergens (10) which, to our knowledge, is the fIrst such study. Twelve matched pairs of DR2+ and DR2-patients were immunized sequentially with giant, western and short ragweed extracts containing known amounts of Amb t V,Amb p V andAmb a V, respectively. Serum was taken before and 12 times after increasing dosages (0.033-11 J.lg) of each Amb V. Eight of 12 DR2+ subjects made IgGAb responses to Amb tV (G.M. = 38 ng/ml), whereas 4/12 DR2-subjects made low levels of IgGAb (G.M. = 3.7 ng/ml); p<0.05 by t test
Three of the four DR2+ nonresponders have atypical MLR responses toward Dw2 typing cells. Preliminary data show that 8 DR2+ subjects have positive immune responses to Amb p V and to Amb a V, with the exception of one DR2+lDw2-subject who failed to respond to Amb p V. However, all 8 DR2-subjects who have completed the Amb p V regimen, and all 5
